New drug combo plus radiation targets tough uterine cancer
NCT ID NCT05603910
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing whether combining two cancer drugs (lenvatinib and pembrolizumab) with a shorter course of pelvic radiation is safe for people with recurrent or unresectable endometrial cancer. The study aims to find the best dose of lenvatinib when used in this triple therapy. About 18 participants will be enrolled to monitor side effects and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenvatinib (Lenvima) and pembrolizumab (Keytruda)
What this could lead to
If this combination is safe, it could lead to a new treatment option for people with recurrent or unresectable endometrial cancer that hasn't responded to standard therapy.
What could go wrong
This is a very early phase 1 trial with only 18 participants, so the main goal is safety, not effectiveness. The combination of drugs and radiation may cause significant side effects, and it's unknown if it will actually shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact